Table 2.
First Author, Year (Ref) | Population | Altitude, m | n | Age, y | Diagnosis Criteria | Glycemia, mg/dL | Crude Prevalence, % | Age- Adjusted Prevalence, % |
---|---|---|---|---|---|---|---|---|
Al-Habori, 2004 (249) | Sana, Yemen | 2300 | 498 | 25–65 | WHO, 1999 | ≥126 or 2-h OGTT ≥200 | 4.6 | |
Chen, 2011 (221) | Lhasa, Tibet, China | 3658–4200 | 1289 | ≥18 | N.A. | ≥126 or 2-h OGTT ≥200 or self-report | 2.9 | |
Faeh, 2009 (250) | German-speaking Switzerland | 259–300 | N.A. | 40–84 | Self-report | 5.8 | ||
German-speaking Switzerland | 300–600 | N.A. | 40–84 | Self-report | 3.8 | |||
German-speaking Switzerland | 600–900 | N.A. | 40–84 | Self-report | 3.4 | |||
German-speaking Switzerland | 900–1200 | N.A. | 40–84 | Self-report | 4.0 | |||
German-speaking Switzerland | 1200–1500 | N.A. | 40–84 | Self-report | 4.3 | |||
German-speaking Switzerland | 1500–1960 | N.A. | 40–84 | Self-report | 5.1 | |||
Malaga, 2010 (216) | Lari, Peru | 3600 | 74 | >18 | N.A. | ≥126 | 1.3 | |
Negi, 2012 (220) | Spiti Valley, India | 3900 | 242 | ≥20 | N.A. | ≥126 | 0.4 | |
Spiti Valley, India | 3100 | 171 | ≥20 | N.A. | ≥126 | 4.1 | ||
Pajuelo-Ramirez, 2010 (50) | Peru | ≥3000 | 959 | ≥20 | ADA, 1997 | ≥126 | 0.9 | |
Peru | 1000–2999 | 808 | ≥20 | ADA, 1997 | ≥126 | 1.6 | ||
Peru | <1000 | 2425 | ≥20 | ADA, 1997 | ≥126 | 2.9 | ||
Posadas-Romero, 1994 (248) | Mexico City, Mexico | 2255a | 805 | 20–90 | WHO, 1985 | ≥140 or self-report | 8.7 | |
Schargrodsky, 2008 (219) | Quito, Ecuador | 2800 | 1638 | 25–64 | ADA, 2003 | ≥126 or self-report | 5.9 | |
Bogota, Colombia | 2625 | 1553 | 25–64 | ADA, 2003 | ≥126 or self-report | 8.1 | ||
Mexico City, Mexico | 2240 | 1722 | 25–64 | ADA, 2003 | ≥126 or self-report | 8.9 | ||
Barquisimeto, Venezuela | 564 | 1848 | 25–64 | ADA, 2003 | ≥126 or self-report | 6.0 | ||
Santiago, Chile | 520 | 1655 | 25–64 | ADA, 2003 | ≥126 or self-report | 7.2 | ||
Lima, Peru | 153 | 1652 | 25–64 | ADA, 2003 | ≥126 or self-report | 4.4 | ||
Buenos Aires, Argentina | 10 | 1482 | 25–64 | ADA, 2003 | ≥126 or self-report | 6.2 | ||
Seclén, 1999 (207) | Huaraz, Peru | 3052 | 77 | >18 | WHO, 1985 | ≥140 or 2-h OGTT ≥200 | 1.3 | |
Waiku, Amazon, Peru | 600 | 54 | >18 | WHO, 1985 | ≥140 or 2-h OGTT ≥200 | 3.7 | ||
Tarapoto, Amazon, Peru | 333 | 90 | >18 | WHO, 1985 | ≥140 or 2-h OGTT ≥200 | 4.4 | ||
Cuñumbuque, Amazon, Peru | 300 | 101 | >18 | WHO, 1985 | ≥140 or 2-h OGTT ≥200 | 2.0 | ||
Lima, Peru | 123 | 158 | >18 | WHO, 1985 | ≥140 or 2-h OGTT ≥200 | 7.6 | ||
Castilla, Peru | 30 | 118 | >18 | WHO, 1985 | ≥140 or 2-h OGTT ≥200 | 6.7 | ||
Segura, 2006 (212) | Andes, Peru | 3493a | N.A. | >18 | - | Self-report | 1.8 | |
Andes, Peru | 2351a | N.A. | >18 | - | Self-report | 2.4 | ||
Amazon, Peru | 168.5a | 1630 | >18 | - | Self-report | 3.9 | ||
Coast, Peru | 31.5a | 7725 | >18 | - | Self-report | 4.3 | ||
Woolcott, 2014 (208) | United States | <1500 | N.A. | ≥20 | - | Self-report | 9.1 | |
United States | ≥1500 | N.A. | ≥20 | - | Self-report | 6.4 |
Abbreviations: ADA, American Diabetes Association; OGTT, oral glucose tolerance test; WHO, World Health Organization; N.A., information not available. Studies were selected on the basis that they were conducted in at least one representative population residing at or above 1500 m.
Median altitude of the cities sampled, using altitude values obtained online.